biosimilars

Showing 15 posts of 87 posts found.

biogen_austria_238

Samsung Bioepis & Biogen receive positive CHMP opinion for ranibizumab biosimilar

June 28, 2021
Sales and Marketing EC, EMA, EU, biosimilars

Samsung Bioepis and Biogen have announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a …

Biosimilars and Brexit: What’s in store for UK’s biosimilar market?

June 2, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, brexit

It’s been 15 years since the first biosimilar entered the market, and the impact of these drugs on the healthcare …

sang-jin_pak

Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars

December 2, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung Bioepis, biosimilars, pharma

Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel’s interview with Sang-Jin …

celltrion1

Europe approves first subcutaneous version of biosimilar infliximab

November 26, 2019
Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …

The coming age of biosimilars

November 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, feature, pharma

With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around …

Pfizer to combine off-patent drug unit Upjohn with Mylan

July 30, 2019
Manufacturing and Production M&A, MA, Mylan, Pfizer, Upjohn, biosimilars, generics, mergers

Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price …

humira_abbott__4

Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US

July 24, 2019
Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma

It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …

fda2outsideweb

FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan

July 24, 2019
Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma

Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …

38707779504_4778627b30_z

Top Ten most popular articles on Pharmafile.com of 2018!

December 21, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Business, biosimilars, brexit, pharma, top 10

Brexit, business and biosimilars, seemed to be the three themes of 2018. As Brexit negotiations reached a stalemate the pharmaceutical …

FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion

November 29, 2018
Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion

The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …

shutterstock_87495637

Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz

November 27, 2018
Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma

The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …

nhs_sign

NHS to save £300 million by switching to Humira biosimilars

November 27, 2018
Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …

310px-pharmacie_in_paulista_avenue

German health minister Jens Spahn calls for faster adoption of biosimilars

November 14, 2018
Research and Development AbbVie, Germany, biosimilars, jens Spahn

Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of …

Latest content